Posted on

Sufentanil Sublingual Tablet (Dsuvia) Gets FDA Approval

The approval is based on data from a multicenter trial in which patients were randomized 2:1 to receive either 30 mcg of the sufentanil sublingual tablet as needed, or placebo, with treatment limited up to 48 hours following the procedure.

Sufentanil Sublingual Tablet (Dsuvia) Gets FDA Approval


Orginally Published At: Pain Management – Pharmacy Times

Leave a Reply

Your email address will not be published. Required fields are marked *